Search clinical trials for: MCLA-128

Total 2533 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Cholangiocarcinoma | Metastatic... and other conditions

United States
National Cancer Institute (NCI)
Radiation Therapy Oncology Group; American College of Radiology Imaging Network

Completed

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Neoplasm

United States
ALK-Abelló A/S

Completed

Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)

Allergy | Rhinitis | Conjunctivitis | Rhinoconjunctivitis
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Recurrent Non-Small Cell Lung Carcinoma | Recurrent Pleural Malignant Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage IV Pleural Malignant Mesothelioma AJCC v7 | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | HLA-A*0201 Positive... and other conditions

United States
Celgene

Completed

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

Healthy Volunteer

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
Assistance Publique Hopitaux De Marseille

Not yet recruiting

Antiplatelet Therapy After Successful Percutaneous Coronary Intervention for Chronically Occluded Coronary Artery (DAPT-CTO)

Chronic Total Occlusion
Zuyderland Medisch Centrum
AtriCure, Inc.

Recruiting

Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum (ICE)

Funnel Chest | Pectus Excavatum

Netherlands
National Cancer Institute (NCI)
AstraZeneca

Active, not recruiting

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Advanced Malignant Solid Neoplasm | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IIIA Lung Non-Small... and other conditions

United States, Canada
Calithera Biosciences, Inc

Terminated

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)

Non-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NRF2 Gene Mutation | NFE2L2 Gene Mutation

United States
GlaxoSmithKline

Completed

Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.

Asthma

Australia, New Zealand
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Adenocarcinoma of the Gastroesophageal Junction | Stage II Gastric Cancer | Stage III Gastric Cancer | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Stomach | Adenocarcinoma of the Esophagus | Stage III Esophageal Cancer | Stage II Esophageal Cancer

United States
EMD Serono

Terminated

Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Germany
French National Agency for Research on AIDS and...
Gilead Sciences; Hoffmann-La Roche

Completed

Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)

HIV Infections | AIDS

France
The Korean Academy of Tuberculosis and Respiratory...
GlaxoSmithKline

Completed

Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea

Chronic Obstructive Pulmonary Disease

Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Advanced Vaginal Adenocarcinoma | Advanced Vaginal Adenosquamous Carcinoma | Advanced Vaginal Squamous Cell Carcinoma | Stage IB2 Cervical Cancer AJCC v6 and v7 | Stage II Cervical Cancer AJCC v7 | Stage II Vaginal Cancer AJCC v6 and v7 | Stage III Vaginal Cancer AJCC v6 and v7 | Stage IIIB Cervical... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma

Small Intestinal Adenocarcinoma | Stage III Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IV Small Intestinal Adenocarcinoma AJCC v8 | Ampulla of Vater Adenocarcinoma | Stage III Ampulla... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
National Cancer Institute (NCI)

Completed

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Advanced Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Advanced Sarcomatoid Renal Cell Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology; Radiation Therapy Oncology Group

Completed

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma | Gliosarcoma | Supratentorial Glioblastoma

United States, Canada, Israel
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Glioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain Neoplasm

United States, Canada
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma AJCC v7

United States
National Institute of Allergy and Infectious Diseases...

Completed

Strategies for Delivering Anti-HIV Therapy in South Africa

HIV Infections

South Africa
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube... and other conditions

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

High Risk Neuroblastoma

United States
Kristine Patterson, MD
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Sex, Aging and Antiretroviral Pharmacokinetics

HIV Infections

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Bone Metastases | Lung Metastases | HER2-positive Breast Cancer | Liver Metastases | Stage IV Breast Cancer | Recurrent Breast Cancer | Soft Tissue Metastases

United States
Université de Sherbrooke

Completed

Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10) (GB10)

Obesity | Type 2 Diabetes

Canada
GlaxoSmithKline

Completed

Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm | HLA-A2 Positive Cells Present

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia,... and other conditions

United States
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Completed

Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IIA Cervical Cancer AJCC v7 | Stage IIB Cervical Cancer AJCC v6 and v7 | Stage III Cervical Cancer AJCC v6 and v7 | Stage IB Cervical Cancer AJCC v6 and v7

United States, Canada
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Colorectal Carcinoma | Refractory Colorectal Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Recurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia, New Zealand, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Refractory Melanoma | BRAF V600 Wild Type | Intracranial Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Active, not recruiting

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC... and other conditions

United States
Eurofarma Laboratorios S.A.

Not yet recruiting

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (TRIPLAR)

Chronic Obstructive Pulmonary Disease

Brazil
Amgen

Completed

Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men

Healthy Volunteers

United States
John Hays
Sanofi

Unknown

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IV Colon Cancer | Stage IV Rectal Cancer

United States
M.D. Anderson Cancer Center

Recruiting

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Chondrosarcoma | Advanced Malignant Solid Neoplasm | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditions

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Active, not recruiting

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Malignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditions

United States
Kirby Institute

Completed

MARCH Renal Substudy (MARCHrenal)

Proteinuria | HIV

Canada, Australia, Germany, Argentina, Japan, Thailand, United Kingdom, Mexico

Search clinical trials for: MCLA-128

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations